{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:42:22Z","timestamp":1784288542581,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40263-018-0517-5","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T06:49:37Z","timestamp":1523342977000},"page":"351-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-7187","authenticated-orcid":false,"given":"Per","family":"Damkier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-4348","authenticated-orcid":false,"given":"Poul","family":"Videbech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"517_CR1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0269881117699361","volume":"31","author":"RH McAllister-Williams","year":"2017","unstructured":"McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol (Oxford). 2017;31:519\u201352.","journal-title":"J Psychopharmacol (Oxford)"},{"key":"517_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acps.12479","volume":"132","author":"ER Larsen","year":"2015","unstructured":"Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;132:1\u201328.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"111","key":"517_CR3","first-page":"1001","volume":"2008","author":"ACOG Committee on Practice Bulletins\u2014Obstetrics","year":"2007","unstructured":"ACOG Committee on Practice Bulletins\u2014Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87) Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2007;2008(111):1001\u201320.","journal-title":"Obstet Gynecol"},{"key":"517_CR4","doi-asserted-by":"crossref","first-page":"h5918","DOI":"10.1136\/bmj.h5918","volume":"532","author":"MS Chisolm","year":"2016","unstructured":"Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918.","journal-title":"BMJ"},{"key":"517_CR5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/15622975.2015.1009163","volume":"16","author":"A Hasan","year":"2015","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenth\u00f8j B, Gattaz WF, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16:142\u201370.","journal-title":"World J Biol Psychiatry"},{"key":"517_CR6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","volume":"73","author":"KF Huybrechts","year":"2016","unstructured":"Huybrechts KF, Hern\u00e1ndez-D\u00edaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73:938\u201346.","journal-title":"JAMA Psychiatry"},{"key":"517_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.12372","volume":"116","author":"ZN Ennis","year":"2015","unstructured":"Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015;116:315\u201320.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"517_CR8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/JCP.0000000000000391","volume":"35","author":"N Terrana","year":"2015","unstructured":"Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2015;35:559\u201365.","journal-title":"J Clin Psychopharmacol"},{"key":"517_CR9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/AOG.0000000000000759","volume":"125","author":"CG Coughlin","year":"2015","unstructured":"Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125:1224\u201335.","journal-title":"Obstet Gynecol"},{"key":"517_CR10","unstructured":"Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. Federal Register. 2014 [cited 14 Nov 2017]. Available at: https:\/\/www.federalregister.gov\/documents\/2014\/12\/04\/2014-28241\/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for."},{"key":"517_CR11","unstructured":"Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data [cited 14 Nov 2017]. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011303.pdf."},{"key":"517_CR12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0b013e3182668568","volume":"32","author":"B K\u00e4ll\u00e9n","year":"2012","unstructured":"K\u00e4ll\u00e9n B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol. 2012;32:608\u201314.","journal-title":"J Clin Psychopharmacol"},{"key":"517_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00004714-200008000-00002","volume":"20","author":"DJ Goldstein","year":"2000","unstructured":"Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000;20:399\u2013403.","journal-title":"J Clin Psychopharmacol"},{"key":"517_CR14","doi-asserted-by":"crossref","first-page":"e0123373","DOI":"10.1371\/journal.pone.0123373","volume":"10","author":"P Shao","year":"2015","unstructured":"Shao P, Ou J, Peng M, Zhao J, Chen J, Wu R. Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. PLoS One. 2015;10:e0123373.","journal-title":"PLoS One"},{"key":"517_CR15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/JCP.0b013e318172b8d5","volume":"28","author":"M Reis","year":"2008","unstructured":"Reis M, K\u00e4ll\u00e9n B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279\u201388.","journal-title":"J Clin Psychopharmacol"},{"key":"517_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. Grade guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"517_CR17","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40697-8","volume-title":"Drugs during pregnancy: methodological aspects","author":"B K\u00e4ll\u00e9n","year":"2016","unstructured":"K\u00e4ll\u00e9n B. Drugs during pregnancy: methodological aspects. New York: Springer; 2016."},{"key":"517_CR18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40471-014-0028-y","volume":"2","author":"SC Tinker","year":"2015","unstructured":"Tinker SC, Gilboa S, Reefhuis J, Jenkins MM, Schaeffer M, Moore CA. Challenges in Studying Modifiable Risk Factors for Birth Defects. Curr Epidemiol Rep. 2015;2:23\u201330.","journal-title":"Curr Epidemiol Rep"},{"key":"517_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/tera.1420450206","volume":"45","author":"MJ Khoury","year":"1992","unstructured":"Khoury MJ, Moore CA, James LM, Cordero JF. The interaction between dysmorphology and epidemiology: methodologic issues of lumping and splitting. Teratology. 1992;45:133\u20138.","journal-title":"Teratology"},{"key":"517_CR20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/bdra.20606","volume":"85","author":"JM Friedman","year":"2009","unstructured":"Friedman JM. Big risks in small groups: the difference between epidemiology and counselling. Birth Defects Res Part A Clin Mol Teratol. 2009;85:720\u20134.","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"key":"517_CR21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.reprotox.2005.03.012","volume":"20","author":"C Schaefer","year":"2005","unstructured":"Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy: 15\u00a0years experience of ENTIS. Reprod Toxicol. 2005;20:331\u201343.","journal-title":"Reprod Toxicol"},{"key":"517_CR22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1741-4520.2005.00062.x","volume":"45","author":"BAJ K\u00e4ll\u00e9n","year":"2005","unstructured":"K\u00e4ll\u00e9n BAJ. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto). 2005;45:44\u201351.","journal-title":"Congenit Anom (Kyoto)"},{"key":"517_CR23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/ph6101221","volume":"6","author":"B K\u00e4ll\u00e9n","year":"2013","unstructured":"K\u00e4ll\u00e9n B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221\u201386.","journal-title":"Pharmaceuticals (Basel)"},{"key":"517_CR24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","volume":"33","author":"F Habermann","year":"2013","unstructured":"Habermann F, Fritzsche J, Fuhlbr\u00fcck F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33:453\u201362.","journal-title":"J Clin Psychopharmacol"},{"key":"517_CR25","doi-asserted-by":"crossref","first-page":"h2298","DOI":"10.1136\/bmj.h2298","volume":"350","author":"SN Vigod","year":"2015","unstructured":"Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298.","journal-title":"BMJ"},{"key":"517_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20230","volume":"20","author":"I Petersen","year":"2016","unstructured":"Petersen I, McCrea RL, Sammon CJ, Osborn DPJ, Evans SJ, Cowen PJ, et al. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health Technol Assess. 2016;20:1\u2013176.","journal-title":"Health Technol Assess"},{"key":"517_CR27","first-page":"e174","volume":"18","author":"G Koren","year":"2011","unstructured":"Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol. 2011;18:e174\u20135.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"517_CR28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2050-6511-14-38","volume":"14","author":"E Brunner","year":"2013","unstructured":"Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14:38.","journal-title":"BMC Pharmacol Toxicol"},{"key":"517_CR29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1176\/appi.ajp.2015.15040506","volume":"173","author":"LS Cohen","year":"2016","unstructured":"Cohen LS, Viguera AC, McInerney KA, Freeman MP, Sosinsky AZ, Moustafa D, et al. Reproductive safety of second-generation antipsychotics: current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Am J Psychiatry. 2016;173:263\u201370.","journal-title":"Am J Psychiatry"},{"key":"517_CR30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4088\/JCP.v66n0406","volume":"66","author":"K McKenna","year":"2005","unstructured":"McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444\u20139.","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"517_CR31","doi-asserted-by":"crossref","first-page":"e003062","DOI":"10.1136\/bmjopen-2013-003062","volume":"3","author":"A Sadowski","year":"2013","unstructured":"Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):e003062.","journal-title":"BMJ Open."},{"key":"517_CR32","doi-asserted-by":"crossref","first-page":"e94788","DOI":"10.1371\/journal.pone.0094788","volume":"9","author":"J Kulkarni","year":"2014","unstructured":"Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9:e94788.","journal-title":"PLoS One"},{"key":"517_CR33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00213-013-3060-6","volume":"228","author":"M Peng","year":"2013","unstructured":"Peng M, Gao K, Ding Y, Ou J, Calabrese JR, Wu R, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology. 2013;228:577\u201384.","journal-title":"Psychopharmacology"},{"key":"517_CR34","volume-title":"Bayley Scale of infant and toddler development","author":"N Bayley","year":"2006","unstructured":"Bayley N. Bayley Scale of infant and toddler development. 3rd ed. San Antonio: The Psychological Corp; 2006.","edition":"3"},{"key":"517_CR35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4088\/JCP.14m09070","volume":"76","author":"A-L Sutter-Dallay","year":"2015","unstructured":"Sutter-Dallay A-L, Bales M, Pambrun E, Glangeaud-Freudenthal NM-C, Wisner KL, Verdoux H. Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry. 2015;76:967\u201373.","journal-title":"J Clin Psychiatry"},{"key":"517_CR36","doi-asserted-by":"crossref","first-page":"j3326","DOI":"10.1136\/bmj.j3326","volume":"358","author":"KF Huybrechts","year":"2017","unstructured":"Huybrechts KF, Bateman BT, Desai RJ, Hernandez-Diaz S, Rough K, Mogun H, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ. 2017;358:j3326.","journal-title":"BMJ"},{"key":"517_CR37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/pds.3749","volume":"24","author":"F Bellet","year":"2015","unstructured":"Bellet F, Beyens M-N, Bernard N, Beghin D, Elefant E, Vial T. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf. 2015;24:368\u201380.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"517_CR38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00737-008-0044-3","volume":"12","author":"CL Wichman","year":"2009","unstructured":"Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009;12:53\u20137.","journal-title":"Arch Womens Ment Health"},{"key":"517_CR39","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. (CDC). Update on overall prevalence of major birth defects\u2014Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57:1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"517_CR40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","volume":"686","author":"H Dolk","year":"2010","unstructured":"Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349\u201364.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"517_CR41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/bdra.20776","volume":"91","author":"B Khoshnood","year":"2011","unstructured":"Khoshnood B, Greenlees R, Loane M, Dolk H, EUROCAT Project Management Committee, EUROCAT Working Group. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Res Part A Clin Mol Teratol. 2011;91(1):16\u201322.","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"key":"517_CR42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00002018-200730030-00006","volume":"30","author":"D Coppola","year":"2007","unstructured":"Coppola D, Russo LJ, Kwarta RF, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30:247\u201364.","journal-title":"Drug Saf"},{"key":"517_CR43","first-page":"197","volume":"6","author":"V Dev","year":"1995","unstructured":"Dev V, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother. 1995;6:197\u2013208.","journal-title":"Rev Contemp Pharmacother."},{"key":"517_CR44","volume-title":"Psychotropic drug directory","author":"S Bazire","year":"2005","unstructured":"Bazire S. Psychotropic drug directory. Salisbury: Fivepin Limited; 2005."},{"key":"517_CR45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archgenpsychiatry.2011.1870","volume":"69","author":"R Bod\u00e9n","year":"2012","unstructured":"Bod\u00e9n R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69:715\u201321.","journal-title":"Arch Gen Psychiatry"},{"key":"517_CR46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1192\/bjp.bp.107.041541","volume":"192","author":"JJ Newham","year":"2008","unstructured":"Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192:333\u20137.","journal-title":"Br J Psychiatry"},{"key":"517_CR47","doi-asserted-by":"crossref","first-page":"e0132280","DOI":"10.1371\/journal.pone.0132280","volume":"10","author":"MJ S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen MJ, Kjaersgaard MIS, Pedersen HS, Vestergaard M, Christensen J, Olsen J, et al. Risk of fetal death after treatment with antipsychotic medications during pregnancy. PLoS One. 2015;10:e0132280.","journal-title":"PLoS One"},{"key":"517_CR48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JCP.0b013e3181db8734","volume":"30","author":"GN Babu","year":"2010","unstructured":"Babu GN, Desai G, Tippeswamy H, Chandra PS. Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol. 2010;30:331\u20132.","journal-title":"J Clin Psychopharmacol"},{"key":"517_CR49","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/ije\/dyt183","volume":"42","author":"RE Brandlistuen","year":"2013","unstructured":"Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol. 2013;42:1702\u201313.","journal-title":"Int J Epidemiol"},{"key":"517_CR50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/bcpt.12322","volume":"116","author":"P Damkier","year":"2015","unstructured":"Damkier P, Potteg\u00e5rd A, dePont Christensen R, Hallas J. Annotations and reflections: pregnancy and paracetamol: methodological considerations on the study of associations between in utero exposure to drugs and childhood neurodevelopment. Basic Clin Pharmacol Toxicol. 2015;116:2\u20135.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"517_CR51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/aur.1591","volume":"9","author":"Z Liew","year":"2016","unstructured":"Liew Z, Ritz B, Virk J, Olsen J. Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: a Danish national birth cohort study. Autism Res. 2016;9(9):951\u20138.","journal-title":"Autism Res"},{"key":"517_CR52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamapediatrics.2013.4914","volume":"168","author":"Z Liew","year":"2014","unstructured":"Liew Z, Ritz B, Rebordosa C, Lee P-C, Olsen J. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014;168:313\u201320.","journal-title":"JAMA Pediatr"},{"key":"517_CR53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.reprotox.2017.05.003","volume":"72","author":"A Ornoy","year":"2017","unstructured":"Ornoy A. Neurobehavioral risks of SSRIs in pregnancy: comparing human and animal data. Reprod Toxicol. 2017;72:191\u2013200.","journal-title":"Reprod Toxicol"},{"key":"517_CR54","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.4088\/JCP.16f10637","volume":"77","author":"C Andrade","year":"2016","unstructured":"Andrade C. Use of acetaminophen (paracetamol) during pregnancy and the risk of autism spectrum disorder in the offspring. J Clin Psychiatry. 2016;77:e152\u20134.","journal-title":"J Clin Psychiatry"},{"key":"517_CR55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S1092852916000699","volume":"22","author":"S Gentile","year":"2017","unstructured":"Gentile S, Fusco ML. Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data. CNS Spectr. 2017;22:273\u201381.","journal-title":"CNS Spectr"},{"key":"517_CR56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archgenpsychiatry.2012.160","volume":"69","author":"KC Johnson","year":"2012","unstructured":"Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69:787\u201394.","journal-title":"Arch Gen Psychiatry"},{"key":"517_CR57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.psym.2012.07.003","volume":"54","author":"L Wakil","year":"2013","unstructured":"Wakil L, Perea E, Penaskovic K, Stuebe A, Meltzer-Brody S. Exacerbation of psychotic disorder during pregnancy in the context of medication discontinuation. Psychosomatics. 2013;54:290\u20133.","journal-title":"Psychosomatics"},{"key":"517_CR58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2014.07.034","volume":"159","author":"I Petersen","year":"2014","unstructured":"Petersen I, McCrea RL, Osborn DJP, Evans S, Pinfold V, Cowen PJ, et al. Discontinuation of antipsychotic medication in pregnancy: a cohort study. Schizophr Res. 2014;159:218\u201325.","journal-title":"Schizophr Res"},{"key":"517_CR59","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/appi.ajp.2007.06101639","volume":"164","author":"AC Viguera","year":"2007","unstructured":"Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817\u201324.","journal-title":"Am J Psychiatry"},{"key":"517_CR60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/neu.2016.60","volume":"29","author":"ER Larsen","year":"2017","unstructured":"Larsen ER, Saric K. Pregnancy and bipolar disorder: the risk of recurrence when discontinuing treatment with mood stabilisers: a systematic review. Acta Neuropsychiatr. 2017;29:259\u201366.","journal-title":"Acta Neuropsychiatr"},{"key":"517_CR61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00737-005-0080-1","volume":"8","author":"V Lindahl","year":"2005","unstructured":"Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005;8:77\u201387.","journal-title":"Arch Womens Ment Health"},{"key":"517_CR62","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","volume":"40","author":"L Hirsch","year":"2017","unstructured":"Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771\u201381.","journal-title":"Drug Saf"},{"key":"517_CR63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","volume":"42","author":"C Deng","year":"2013","unstructured":"Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am. 2013;42:545\u201363.","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0517-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0517-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0517-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:38:06Z","timestamp":1612834686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0517-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0517-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"10 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review does not contain individual-level data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Per Damkier and Poul Videbech declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This review was not funded.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}